1. Scrip
  2. >>New Products

AstraZeneca’s Oncology Strategy Yields Victories

Tagrisso Adjuvant Data, Koselugo NF1 Approval Are Signs Of Progress

 
• By Mandy Jackson

The company stopped the Phase III ADAURA study for Tagrisso early due to overwhelming efficacy and the US FDA approved selumetinib in a rare pediatric disease.

DNA strand and Cancer Cell Oncology Research Concept 3D rendering
The targeted therapies Tagrisso and selumetinib met key milestones • Source: Shutterstock

AstraZeneca PLC made progress on two fronts in its quest to build its oncology portfolio with the early unblinding of the Phase III ADAURA clinical trial of Tagrisso (osimertinib) in the adjuvant lung cancer setting and with US Food and Drug Administration approval for Koselugo (selumetinib) in its first-ever indication.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

 
• By Joseph Haas

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.

Could There Be A Cure For Cardiometabolic Disease? Novo Nordisk Foundation Wants To Help Academics Find Out

 
• By Andrew McConaghie

The not-for-profit’s senior vice president Martin Ridderstråle explains how it is expanding grants for basic research to improve "human and planetary" health.

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.